Technical Analysis for SAGE - Sage Therapeutics, Inc.

Grade Last Price % Change Price Change
F 5.94 2.24% 0.13
SAGE closed up 2.24 percent on Tuesday, November 5, 2024, on 85 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.24%
Calm After Storm Range Contraction 2.24%
New 52 Week Low Weakness 2.24%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 8 hours ago
Possible NR7 about 9 hours ago
Fell Below Previous Day's Low about 14 hours ago
Down 2 % about 14 hours ago
Down 1% about 14 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sage Therapeutics, Inc. Description

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Clinical Development Pharmacology Central Nervous System Disorders Nervous System Disorders Toxicology Antidepressants Seizure Adjunctive Therapy Anticonvulsants Gabaa Receptor Positive Allosteric Modulators Neurosteroids Status Epilepticus

Is SAGE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.26
52 Week Low 5.64
Average Volume 677,815
200-Day Moving Average 13.17
50-Day Moving Average 7.29
20-Day Moving Average 7.07
10-Day Moving Average 7.09
Average True Range 0.52
RSI (14) 35.06
ADX 27.11
+DI 16.49
-DI 37.13
Chandelier Exit (Long, 3 ATRs) 7.14
Chandelier Exit (Short, 3 ATRs) 7.20
Upper Bollinger Bands 8.72
Lower Bollinger Band 5.42
Percent B (%b) 0.16
BandWidth 46.62
MACD Line -0.28
MACD Signal Line -0.10
MACD Histogram -0.187
Fundamentals Value
Market Cap 357.03 Million
Num Shares 60.1 Million
EPS -10.98
Price-to-Earnings (P/E) Ratio -0.54
Price-to-Sales 124.79
Price-to-Book 1.74
PEG Ratio 0.74
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.41
Resistance 3 (R3) 6.36 6.15 6.33
Resistance 2 (R2) 6.15 6.03 6.18 6.30
Resistance 1 (R1) 6.05 5.96 6.10 6.10 6.28
Pivot Point 5.84 5.84 5.87 5.87 5.84
Support 1 (S1) 5.74 5.72 5.79 5.79 5.60
Support 2 (S2) 5.53 5.65 5.56 5.58
Support 3 (S3) 5.43 5.53 5.55
Support 4 (S4) 5.48